Natera, Inc. (NASDAQ:NTRA) CFO Michael Burkes Brophy Sells 2,273 Shares

Posted by MarketBeat News on Jan 25th, 2023

Natera, Inc. (NASDAQ:NTRA – Get Rating) CFO Michael Burkes Brophy sold 2,273 shares of Natera stock in a transaction on Monday, January 23rd. The shares were sold at an average price of $41.56, for a total transaction of $94,465.88. Following the completion of the sale, the chief financial officer now owns 103,023 shares of the company’s stock, valued at approximately $4,281,635.88. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link.

Michael Burkes Brophy also recently made the following trade(s):

On Tuesday, January 3rd, Michael Burkes Brophy sold 3,644 shares of Natera stock. The shares were sold at an average price of $39.55, for a total transaction of $144,120.20.
On Wednesday, December 28th, Michael Burkes Brophy sold 915 shares of Natera stock. The shares were sold at an average price of $39.84, for a total transaction of $36,453.60.
On Friday, December 23rd, Michael Burkes Brophy sold 429 shares of Natera stock. The shares were sold at an average price of $42.30, for a total transaction of $18,146.70.

Natera Price Performance

NTRA opened at $42.94 on Wednesday. The company has a debt-to-equity ratio of 0.78, a current ratio of 3.10 and a quick ratio of 2.95. The company has a market capitalization of $4.19 billion, a price-to-earnings ratio of -7.56 and a beta of 1.28. The firm’s fifty day moving average price is $39.55 and its two-hundred day moving average price is $44.06. Natera, Inc. has a 1 year low of $26.10 and a 1 year high of $74.82.

Want More Great Investing Ideas?

Natera (NASDAQ:NTRA – Get Rating) last released its earnings results on Tuesday, November 8th. The medical research company reported ($1.25) EPS for the quarter, topping analysts’ consensus estimates of ($1.42) by $0.17. The company had revenue of $210.64 million for the quarter, compared to analysts’ expectations of $208.31 million. Natera had a negative return on equity of 109.07% and a negative net margin of 70.34%. As a group, analysts anticipate that Natera, Inc. will post -5.64 earnings per share for the current fiscal year.

Institutional Investors Weigh In On Natera

Hedge funds have recently made changes to their positions in the business. Ronald Blue Trust Inc. bought a new stake in shares of Natera during the 2nd quarter worth $26,000. Parallel Advisors LLC raised its stake in Natera by 84.2% in the 2nd quarter. Parallel Advisors LLC now owns 829 shares of the medical research company’s stock valued at $29,000 after acquiring an additional 379 shares during the period. Assetmark Inc. raised its stake in Natera by 93.6% in the 2nd quarter. Assetmark Inc. now owns 873 shares of the medical research company’s stock valued at $31,000 after acquiring an additional 422 shares during the period. Quadrant Capital Group LLC raised its stake in Natera by 4,595.2% in the 2nd quarter. Quadrant Capital Group LLC now owns 986 shares of the medical research company’s stock valued at $35,000 after acquiring an additional 965 shares during the period. Finally, First Horizon Advisors Inc. raised its stake in Natera by 970.2% in the 3rd quarter. First Horizon Advisors Inc. now owns 1,006 shares of the medical research company’s stock valued at $44,000 after acquiring an additional 912 shares during the period. 93.81% of the stock is currently owned by institutional investors.

Analyst Ratings Changes

Several analysts have recently weighed in on NTRA shares. Raymond James upgraded shares of Natera from a “market perform” rating to an “outperform” rating and set a $58.00 price objective for the company in a research note on Wednesday, January 18th. StockNews.com began coverage on shares of Natera in a research report on Wednesday, October 12th. They issued a “sell” rating for the company. Credit Suisse Group reduced their price target on shares of Natera from $70.00 to $55.00 and set an “outperform” rating for the company in a research report on Monday, November 14th. Robert W. Baird reduced their price target on shares of Natera from $72.00 to $65.00 in a research report on Wednesday, November 9th. Finally, Stephens reduced their price target on shares of Natera to $67.00 in a research report on Wednesday, November 16th. One analyst has rated the stock with a sell rating and seven have assigned a buy rating to the stock. Based on data from MarketBeat.com, the stock has an average rating of “Moderate Buy” and an average target price of $80.00.

Natera Company Profile

(Get Rating)

Natera, Inc, a diagnostics company, develops and commercializes molecular testing services worldwide. It offers Panorama, a non-invasive prenatal test that screens for chromosomal abnormalities of a fetus with a blood draw from the mother, as well as twin pregnancies for zygosity; Vistara, a single-gene mutations screening test to identify single-gene disorder; Horizon carrier screening to determine carrier status for various genetic diseases; and Spectrum to identify chromosomal anomalies or inherited genetic conditions during an in vitro fertilization cycle.